SCHEMBL3570460

SCHEMBL3570460

CC(C)(C)OC(=O)N1CC(C(C)(C)N)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.51
USP2 O75604 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
RECQL P46063 1/20 0.44
GPR119 Q8TDV5 3/20 0.43
HPGD P15428 1/20 0.42
EPHX1 P07099 1/20 0.41
PDE4B Q07343 1/20 0.40
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
NAMPT P43490 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
RORC P51449 1/20 0.39
EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3568385 0.86 HPGD (0.49) NR1H2USP2SMN1; SMN2RECQLGPR119
SCHEMBL3564626 0.86 HPGD (0.49) NR1H2USP2SMN1; SMN2RECQLGPR119
SCHEMBL8395258 0.84 NR1H2 (0.54) NR1H2USP2SMN1; SMN2RECQLGPR119
SCHEMBL23090070 0.83 MEN1 (0.52) NR1H2USP2SMN1; SMN2RECQLGPR119
SCHEMBL572706 0.82 NR1H2 (0.53) NR1H2USP2SMN1; SMN2RECQLGPR119
SCHEMBL6402693 0.81 HPGD (0.55) USP2SMN1; SMN2RECQLGPR119HPGD
SCHEMBL30875141 0.81 NR1H2 (0.51) NR1H2USP2SMN1; SMN2RECQLHPGD
SCHEMBL6634170 0.81 NR1H2 (0.51) NR1H2USP2SMN1; SMN2RECQLGPR119
SCHEMBL14140634 0.80 NR1H2 (0.54) NR1H2USP2SMN1; SMN2RECQLGPR119
SCHEMBL13779791 0.80 NR1H2 (0.54) NR1H2USP2SMN1; SMN2RECQLGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3299358-A1 AMIDE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2018-03-28 EP disclosed
EP-1702917-B1 AMIDE DERIVATIVE AND MEDICINE NIPPON SHINYAKU CO LTD (JP) 2017-08-02 EP disclosed
US-7728131-B2 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia NIPPON SHINYAKU CO., LTD. (JP) 2010-06-01 US disclosed
US-20080293940-A1 Amide Derivative and Medicine NIPPON SHINYAKU CO., LTD. (JP) 2008-11-27 US disclosed
EP-1702917-A1 AMIDE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2006-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293940-A1 Amide Derivative and Medicine ABL2, ABL1, BCR NR1H2 853/4885USP2 1714/4885SMN1; SMN2 4694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.